Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2003 Sep;62(9):817–824. doi: 10.1136/ard.62.9.817

International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis

J Braun 1, T Pham 1, J Sieper 1, J Davis 1, S van der Linden 1, M Dougados 1, D van der Heijde 1
PMCID: PMC1754665  PMID: 12922952

Abstract

Objective: To obtain an international consensus about the use of anti-tumour necrosis factor α (anti-TNFα) for treating patients with ankylosing spondylitis (AS).

Methods: These recommendations were developed by a review of published reports in combination with expert opinion, including a Delphi exercise, and a consensus meeting of the ASsessments in AS (ASAS) Working Group.

Results: The final consensus comprises the following requirements: (1) For the initiation of anti-TNFα therapy: (a) a diagnosis of definitive AS; (b) presence of active disease for at least four weeks as defined by both a sustained Bath AS Disease Activity Index (BASDAI) of at least 4 and an expert opinion based on clinical features, acute phase reactants, and imaging modalities; (c) presence of refractory disease defined by failure of at least two non-steroidal anti-inflammatory drugs during a single three month period, failure of intra-articular steroids if indicated, and failure of sulfasalazine in patients with peripheral arthritis; (d) application and implementation of the usual precautions and contraindications for biological therapy. (2) For the monitoring of anti-TNFα therapy: both the BASDAI and the ASAS core set for clinical practice should be followed regularly. (3) For the discontinuation of anti-TNFα therapy: in non-responders, consideration should be made after 6–12 weeks' treatment. Response is defined as improvement of (a) at least 50% or 2 units (on a 0–10 scale) of the BASDAI, (b) expert opinion that treatment should be continued.

Conclusion: This consensus statement on anti-TNFα treatment in AS may be used for guidance in clinical decision making and as the basis for the development of guidelines. Evaluation of the healthcare consequences of this consensus is subject to further research by the ASAS group.

Full Text

The Full Text of this article is available as a PDF (84.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson J. J., Baron G., van der Heijde D., Felson D. T., Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum. 2001 Aug;44(8):1876–1886. doi: 10.1002/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F. [DOI] [PubMed] [Google Scholar]
  2. Antoni C., Braun J. Side effects of anti-TNF therapy: current knowledge. Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S152–S157. [PubMed] [Google Scholar]
  3. Baert Filip, Noman Maja, Vermeire Severine, Van Assche Gert, D' Haens Geert, Carbonez An, Rutgeerts Paul. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003 Feb 13;348(7):601–608. doi: 10.1056/NEJMoa020888. [DOI] [PubMed] [Google Scholar]
  4. Boonen A., Chorus A., Miedema H., van der Heijde D., van der Tempel H., van der Linden S. Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann Rheum Dis. 2001 Apr;60(4):353–358. doi: 10.1136/ard.60.4.353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Boonen A., van der Heijde D., Landewé R., Spoorenberg A., Schouten H., Rutten-van Mölken M., Guillemin F., Dougados M., Mielants H., de Vlam K. Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis. 2002 May;61(5):429–437. doi: 10.1136/ard.61.5.429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Brandt J., Haibel H., Cornely D., Golder W., Gonzalez J., Reddig J., Thriene W., Sieper J., Braun J. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum. 2000 Jun;43(6):1346–1352. doi: 10.1002/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO;2-E. [DOI] [PubMed] [Google Scholar]
  7. Brandt J., Haibel H., Sieper J., Reddig J., Braun J. Infliximab treatment of severe ankylosing spondylitis: one-year followup. Arthritis Rheum. 2001 Dec;44(12):2936–2937. doi: 10.1002/1529-0131(200112)44:12<2936::aid-art483>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  8. Brandt J., Khariouzov A., Listing J., Haibel H., Sörensen H., Grassnickel L., Rudwaleit M., Sieper J., Braun J. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. 2003 Jun;48(6):1667–1675. doi: 10.1002/art.11017. [DOI] [PubMed] [Google Scholar]
  9. Braun J., Baraliakos X., Golder W., Brandt J., Rudwaleit M., Listing J., Bollow M., Sieper J., Van Der Heijde D. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum. 2003 Apr;48(4):1126–1136. doi: 10.1002/art.10883. [DOI] [PubMed] [Google Scholar]
  10. Braun J., Bollow M., Neure L., Seipelt E., Seyrekbasan F., Herbst H., Eggens U., Distler A., Sieper J. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum. 1995 Apr;38(4):499–505. doi: 10.1002/art.1780380407. [DOI] [PubMed] [Google Scholar]
  11. Braun J., Bollow M., Remlinger G., Eggens U., Rudwaleit M., Distler A., Sieper J. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum. 1998 Jan;41(1):58–67. doi: 10.1002/1529-0131(199801)41:1<58::AID-ART8>3.0.CO;2-G. [DOI] [PubMed] [Google Scholar]
  12. Braun J., Brandt J., Listing J., Zink A., Alten R., Golder W., Gromnica-Ihle E., Kellner H., Krause A., Schneider M. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002 Apr 6;359(9313):1187–1193. doi: 10.1016/s0140-6736(02)08215-6. [DOI] [PubMed] [Google Scholar]
  13. Braun J., Pincus T. Mortality, course of disease and prognosis of patients with ankylosing spondylitis. Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S16–S22. [PubMed] [Google Scholar]
  14. Braun J., van der Heijde D., Dougados M., Emery P., Khan M. A., Sieper J., van der Linden Sj. Staging of patients with ankylosing spondylitis: a preliminary proposal. Ann Rheum Dis. 2002 Dec;61 (Suppl 3):iii9–ii23. doi: 10.1136/ard.61.suppl_3.iii19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Braun J., van der Heijde D. Imaging and scoring in ankylosing spondylitis. Best Pract Res Clin Rheumatol. 2002 Sep;16(4):573–604. [PubMed] [Google Scholar]
  16. Braun Juergen, Sieper Joachim. Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches. Arthritis Res. 2002 Aug 6;4(5):307–321. doi: 10.1186/ar592. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Breban M., Vignon E., Claudepierre P., Devauchelle V., Wendling D., Lespessailles E., Euller-Ziegler L., Sibilia J., Perdriger A., Mezières M. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology (Oxford) 2002 Nov;41(11):1280–1285. doi: 10.1093/rheumatology/41.11.1280. [DOI] [PubMed] [Google Scholar]
  18. Calin A., Garrett S., Whitelock H., Kennedy L. G., O'Hea J., Mallorie P., Jenkinson T. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994 Dec;21(12):2281–2285. [PubMed] [Google Scholar]
  19. D'Agostino Maria Antonietta, Breban Maxime, Said-Nahal Roula, Dougados Maxime. Refractory inflammatory heel pain in spondylarthropathy: a significant response to infliximab documented by ultrasound. Arthritis Rheum. 2002 Mar;46(3):840-1, author reply 841-3. doi: 10.1002/art.513. [DOI] [PubMed] [Google Scholar]
  20. Dougados M., van der Linden S., Juhlin R., Huitfeldt B., Amor B., Calin A., Cats A., Dijkmans B., Olivieri I., Pasero G. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum. 1991 Oct;34(10):1218–1227. doi: 10.1002/art.1780341003. [DOI] [PubMed] [Google Scholar]
  21. Furst D. E., Breedveld F. C., Kalden J. R., Smolen J. S., Antoni C. E., Bijlsma J. W. J., Burmester G. R., Cronstein B., Keystone E. C., Kavanaugh A. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002). Ann Rheum Dis. 2002 Nov;61 (Suppl 2):ii2–ii7. doi: 10.1136/ard.61.suppl_2.ii2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Garrett S., Jenkinson T., Kennedy L. G., Whitelock H., Gaisford P., Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994 Dec;21(12):2286–2291. [PubMed] [Google Scholar]
  23. Gorman Jennifer D., Sack Kenneth E., Davis John C., Jr Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002 May 2;346(18):1349–1356. doi: 10.1056/NEJMoa012664. [DOI] [PubMed] [Google Scholar]
  24. Gran J. T., Husby G. The epidemiology of ankylosing spondylitis. Semin Arthritis Rheum. 1993 Apr;22(5):319–334. doi: 10.1016/s0049-0172(05)80011-3. [DOI] [PubMed] [Google Scholar]
  25. Hadi A., Hickling P., Brown M., Al-Nahhas A. Scintigraphic evidence of effect of infliximab on disease activity in ankylosing spondylitis. Rheumatology (Oxford) 2002 Jan;41(1):114–116. doi: 10.1093/rheumatology/41.1.114. [DOI] [PubMed] [Google Scholar]
  26. Kruithof E., Van den Bosch F., Baeten D., Herssens A., De Keyser F., Mielants H., Veys E. M. Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis. 2002 Mar;61(3):207–212. doi: 10.1136/ard.61.3.207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Leirisalo-Repo M. Prognosis, course of disease, and treatment of the spondyloarthropathies. Rheum Dis Clin North Am. 1998 Nov;24(4):737-51, viii. doi: 10.1016/s0889-857x(05)70039-9. [DOI] [PubMed] [Google Scholar]
  28. Maksymowych Walter P., Inman Robert D., Gladman Dafna, Thomson Glen, Stone Millicent, Karsh Jacob, Russell Anthony S., Spondyloarthritis Research Consortium of Canada (SPARCC) Canadian Rheumatology Association Consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis. J Rheumatol. 2003 Jun;30(6):1356–1363. [PubMed] [Google Scholar]
  29. Maksymowych Walter P., Jhangri Gian S., Lambert Robert G., Mallon Cathy, Buenviaje Heidi, Pedrycz Ewa, Luongo Rolfe, Russell Anthony S. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol. 2002 May;29(5):959–965. [PubMed] [Google Scholar]
  30. Marzo-Ortega H., McGonagle D., O'Connor P., Emery P. Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis. Ann Rheum Dis. 2003 Jan;62(1):74–76. doi: 10.1136/ard.62.1.74. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Marzo-Ortega H., McGonagle D., O'Connor P., Emery P. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum. 2001 Sep;44(9):2112–2117. doi: 10.1002/1529-0131(200109)44:9<2112::AID-ART363>3.0.CO;2-H. [DOI] [PubMed] [Google Scholar]
  32. Mease P. J., Goffe B. S., Metz J., VanderStoep A., Finck B., Burge D. J. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000 Jul 29;356(9227):385–390. doi: 10.1016/S0140-6736(00)02530-7. [DOI] [PubMed] [Google Scholar]
  33. Pham T., van der Heijde D., Calin A., Khan M. A., van der Linden Sj, Bellamy N., Dougados M., ASAS Working Group Initiation of biological agents in patients with ankylosing spondylitis: results of a Delphi study by the ASAS Group. Ann Rheum Dis. 2003 Sep;62(9):812–816. doi: 10.1136/ard.62.9.812. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Stone M., Salonen D., Lax M., Payne U., Lapp V., Inman R. Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. J Rheumatol. 2001 Jul;28(7):1605–1614. [PubMed] [Google Scholar]
  35. Van Den Bosch Filip, Kruithof Elli, Baeten Dominique, Herssens Annemie, de Keyser Filip, Mielants Herman, Veys Eric M. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum. 2002 Mar;46(3):755–765. doi: 10.1002/art.511. [DOI] [PubMed] [Google Scholar]
  36. Van den Bosch F., Kruithof E., Baeten D., De Keyser F., Mielants H., Veys E. M. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis. 2000 Jun;59(6):428–433. doi: 10.1136/ard.59.6.428. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Ward M. M. Health-related quality of life in ankylosing spondylitis: a survey of 175 patients. Arthritis Care Res. 1999 Aug;12(4):247–255. [PubMed] [Google Scholar]
  38. Zink A., Braun J., Listing J., Wollenhaupt J. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis--results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol. 2000 Mar;27(3):613–622. [PubMed] [Google Scholar]
  39. Zink A., Listing J., Klindworth C., Zeidler H., German Collaboratrive Arthritis Centres The national database of the German Collaborative Arthritis Centres: I. Structure, aims, and patients. Ann Rheum Dis. 2001 Mar;60(3):199–206. doi: 10.1136/ard.60.3.199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. van der Heijde D., Bellamy N., Calin A., Dougados M., Khan M. A., van der Linden S. Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. J Rheumatol. 1997 Nov;24(11):2225–2229. [PubMed] [Google Scholar]
  41. van der Heijde D., Calin A., Dougados M., Khan M. A., van der Linden S., Bellamy N. Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis. J Rheumatol. 1999 Apr;26(4):951–954. [PubMed] [Google Scholar]
  42. van der Linden S. M., Valkenburg H. A., de Jongh B. M., Cats A. The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. A comparison of relatives of spondylitis patients with the general population. Arthritis Rheum. 1984 Mar;27(3):241–249. doi: 10.1002/art.1780270301. [DOI] [PubMed] [Google Scholar]
  43. van der Linden S., Valkenburg H. A., Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984 Apr;27(4):361–368. doi: 10.1002/art.1780270401. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES